nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—prostate cancer—bone cancer	0.763	1	CtDrD
Nilutamide—POR—Doxorubicin—bone cancer	0.169	0.909	CbGbCtD
Nilutamide—CYP2C9—Cisplatin—bone cancer	0.017	0.0914	CbGbCtD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00635	0.274	CbGpPWpGaD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00125	0.0542	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—T—bone cancer	0.000977	0.0422	CbGpPWpGaD
Nilutamide—Flutamide—CYP3A4—bone cancer	0.000959	0.522	CrCbGaD
Nilutamide—Enzalutamide—CYP3A4—bone cancer	0.000877	0.478	CrCbGaD
Nilutamide—AR—Nuclear Receptors—NR1I2—bone cancer	0.000706	0.0305	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—FEV—bone cancer	0.000673	0.0291	CbGpPWpGaD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000668	0.0289	CbGpPWpGaD
Nilutamide—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000638	0.0276	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000596	0.0258	CbGpPWpGaD
Nilutamide—AR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000558	0.0241	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000544	0.0235	CbGpPWpGaD
Nilutamide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00052	0.0225	CbGpPWpGaD
Nilutamide—Interstitial pneumonia—Methotrexate—bone cancer	0.00047	0.0185	CcSEcCtD
Nilutamide—Pain—Carboplatin—bone cancer	0.00043	0.017	CcSEcCtD
Nilutamide—Body temperature increased—Carboplatin—bone cancer	0.000398	0.0157	CcSEcCtD
Nilutamide—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000322	0.0139	CbGpPWpGaD
Nilutamide—Interstitial lung disease—Methotrexate—bone cancer	0.000321	0.0126	CcSEcCtD
Nilutamide—Lung disorder—Methotrexate—bone cancer	0.000321	0.0126	CcSEcCtD
Nilutamide—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.00031	0.0134	CbGpPWpGaD
Nilutamide—Gastrointestinal haemorrhage—Cisplatin—bone cancer	0.0003	0.0118	CcSEcCtD
Nilutamide—Lung disorder—Epirubicin—bone cancer	0.0003	0.0118	CcSEcCtD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000294	0.0127	CbGpPWpGaD
Nilutamide—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000288	0.0124	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000287	0.0124	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—ZNF77—bone cancer	0.000285	0.0123	CbGpPWpGaD
Nilutamide—Blood creatinine increased—Cisplatin—bone cancer	0.000281	0.0111	CcSEcCtD
Nilutamide—Lung disorder—Doxorubicin—bone cancer	0.000278	0.0109	CcSEcCtD
Nilutamide—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000277	0.012	CbGpPWpGaD
Nilutamide—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.00027	0.0107	CcSEcCtD
Nilutamide—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000262	0.0113	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000257	0.0111	CbGpPWpGaD
Nilutamide—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000252	0.0109	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000234	0.0101	CbGpPWpGaD
Nilutamide—Cough increased—Epirubicin—bone cancer	0.000232	0.00914	CcSEcCtD
Nilutamide—Nocturia—Epirubicin—bone cancer	0.000229	0.00902	CcSEcCtD
Nilutamide—Creatinine increased—Epirubicin—bone cancer	0.000223	0.00879	CcSEcCtD
Nilutamide—Bone pain—Epirubicin—bone cancer	0.000222	0.00874	CcSEcCtD
Nilutamide—Melaena—Methotrexate—bone cancer	0.000222	0.00874	CcSEcCtD
Nilutamide—Cough increased—Doxorubicin—bone cancer	0.000215	0.00846	CcSEcCtD
Nilutamide—Phosphatase alkaline increased—Epirubicin—bone cancer	0.000212	0.00837	CcSEcCtD
Nilutamide—Nocturia—Doxorubicin—bone cancer	0.000212	0.00835	CcSEcCtD
Nilutamide—Melaena—Epirubicin—bone cancer	0.000207	0.00818	CcSEcCtD
Nilutamide—Creatinine increased—Doxorubicin—bone cancer	0.000206	0.00814	CcSEcCtD
Nilutamide—Bone pain—Doxorubicin—bone cancer	0.000205	0.00808	CcSEcCtD
Nilutamide—Urinary tract disorder—Cisplatin—bone cancer	0.000205	0.00808	CcSEcCtD
Nilutamide—Urethral disorder—Cisplatin—bone cancer	0.000204	0.00802	CcSEcCtD
Nilutamide—Gynaecomastia—Methotrexate—bone cancer	0.000203	0.008	CcSEcCtD
Nilutamide—Blood urea increased—Epirubicin—bone cancer	0.000201	0.0079	CcSEcCtD
Nilutamide—Visual impairment—Cisplatin—bone cancer	0.0002	0.00789	CcSEcCtD
Nilutamide—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000198	0.00854	CbGpPWpGaD
Nilutamide—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.000197	0.00774	CcSEcCtD
Nilutamide—Melaena—Doxorubicin—bone cancer	0.000192	0.00756	CcSEcCtD
Nilutamide—AR—Notch-mediated HES/HEY network—RB1—bone cancer	0.000187	0.0081	CbGpPWpGaD
Nilutamide—Blood urea increased—Doxorubicin—bone cancer	0.000186	0.00731	CcSEcCtD
Nilutamide—Abnormal vision—Epirubicin—bone cancer	0.000185	0.0073	CcSEcCtD
Nilutamide—Alopecia—Cisplatin—bone cancer	0.000184	0.00723	CcSEcCtD
Nilutamide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00018	0.00778	CbGpPWpGaD
Nilutamide—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000177	0.00698	CcSEcCtD
Nilutamide—Visual disturbance—Methotrexate—bone cancer	0.000174	0.00685	CcSEcCtD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000172	0.00742	CbGpPWpGaD
Nilutamide—Abnormal vision—Doxorubicin—bone cancer	0.000171	0.00675	CcSEcCtD
Nilutamide—Ill-defined disorder—Cisplatin—bone cancer	0.000168	0.00661	CcSEcCtD
Nilutamide—Anaemia—Cisplatin—bone cancer	0.000167	0.00658	CcSEcCtD
Nilutamide—Hot flush—Epirubicin—bone cancer	0.000165	0.00649	CcSEcCtD
Nilutamide—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000164	0.00646	CcSEcCtD
Nilutamide—Menopausal symptoms—Epirubicin—bone cancer	0.000163	0.00644	CcSEcCtD
Nilutamide—Malaise—Cisplatin—bone cancer	0.000163	0.00642	CcSEcCtD
Nilutamide—Leukopenia—Cisplatin—bone cancer	0.000162	0.00638	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000161	0.00694	CbGpPWpGaD
Nilutamide—Cardiac failure—Epirubicin—bone cancer	0.000158	0.00623	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000154	0.00608	CcSEcCtD
Nilutamide—Hot flush—Doxorubicin—bone cancer	0.000153	0.00601	CcSEcCtD
Nilutamide—Discomfort—Cisplatin—bone cancer	0.000152	0.00599	CcSEcCtD
Nilutamide—Menopausal symptoms—Doxorubicin—bone cancer	0.000151	0.00596	CcSEcCtD
Nilutamide—Oedema—Cisplatin—bone cancer	0.000148	0.00581	CcSEcCtD
Nilutamide—AR—FOXA1 transcription factor network—JUN—bone cancer	0.000146	0.00633	CbGpPWpGaD
Nilutamide—Cardiac failure—Doxorubicin—bone cancer	0.000146	0.00576	CcSEcCtD
Nilutamide—AR—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000145	0.00628	CbGpPWpGaD
Nilutamide—Blood creatinine increased—Epirubicin—bone cancer	0.000144	0.00569	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000143	0.00562	CcSEcCtD
Nilutamide—Hyperhidrosis—Cisplatin—bone cancer	0.000143	0.00562	CcSEcCtD
Nilutamide—Dry skin—Epirubicin—bone cancer	0.000141	0.00557	CcSEcCtD
Nilutamide—Anorexia—Cisplatin—bone cancer	0.000141	0.00554	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00014	0.00606	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000139	0.00603	CbGpPWpGaD
Nilutamide—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000139	0.00547	CcSEcCtD
Nilutamide—AR—Gene Expression—ZNF77—bone cancer	0.000137	0.00592	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000137	0.00591	CbGpPWpGaD
Nilutamide—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000136	0.00536	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000135	0.00583	CbGpPWpGaD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000134	0.00578	CbGpPWpGaD
Nilutamide—Blood creatinine increased—Doxorubicin—bone cancer	0.000134	0.00527	CcSEcCtD
Nilutamide—Influenza—Epirubicin—bone cancer	0.000133	0.00525	CcSEcCtD
Nilutamide—Paraesthesia—Cisplatin—bone cancer	0.000133	0.00522	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Methotrexate—bone cancer	0.000132	0.00521	CcSEcCtD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000132	0.00571	CbGpPWpGaD
Nilutamide—Dyspnoea—Cisplatin—bone cancer	0.000132	0.00518	CcSEcCtD
Nilutamide—Erectile dysfunction—Methotrexate—bone cancer	0.000131	0.00517	CcSEcCtD
Nilutamide—Dry skin—Doxorubicin—bone cancer	0.000131	0.00515	CcSEcCtD
Nilutamide—Angina pectoris—Epirubicin—bone cancer	0.00013	0.00511	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000128	0.00506	CcSEcCtD
Nilutamide—Decreased appetite—Cisplatin—bone cancer	0.000128	0.00505	CcSEcCtD
Nilutamide—Pneumonia—Methotrexate—bone cancer	0.000128	0.00503	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Cisplatin—bone cancer	0.000127	0.00502	CcSEcCtD
Nilutamide—Depression—Methotrexate—bone cancer	0.000127	0.00499	CcSEcCtD
Nilutamide—AR—Regulation of Androgen receptor activity—JUN—bone cancer	0.000126	0.00546	CbGpPWpGaD
Nilutamide—Pain—Cisplatin—bone cancer	0.000126	0.00497	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000126	0.00496	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000124	0.00538	CbGpPWpGaD
Nilutamide—Upper respiratory tract infection—Epirubicin—bone cancer	0.000124	0.00488	CcSEcCtD
Nilutamide—Influenza—Doxorubicin—bone cancer	0.000123	0.00486	CcSEcCtD
Nilutamide—Sweating—Methotrexate—bone cancer	0.000122	0.0048	CcSEcCtD
Nilutamide—Feeling abnormal—Cisplatin—bone cancer	0.000122	0.00479	CcSEcCtD
Nilutamide—Haematuria—Methotrexate—bone cancer	0.000121	0.00477	CcSEcCtD
Nilutamide—Weight decreased—Epirubicin—bone cancer	0.000121	0.00475	CcSEcCtD
Nilutamide—Hyperglycaemia—Epirubicin—bone cancer	0.00012	0.00474	CcSEcCtD
Nilutamide—Angina pectoris—Doxorubicin—bone cancer	0.00012	0.00473	CcSEcCtD
Nilutamide—Pneumonia—Epirubicin—bone cancer	0.00012	0.00471	CcSEcCtD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000119	0.00516	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000118	0.0051	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.000118	0.00508	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000117	0.00505	CbGpPWpGaD
Nilutamide—Body temperature increased—Cisplatin—bone cancer	0.000117	0.0046	CcSEcCtD
Nilutamide—Urinary tract infection—Epirubicin—bone cancer	0.000115	0.00455	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000115	0.00452	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000114	0.00494	CbGpPWpGaD
Nilutamide—Sweating—Epirubicin—bone cancer	0.000114	0.00449	CcSEcCtD
Nilutamide—Haematuria—Epirubicin—bone cancer	0.000113	0.00446	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000113	0.0049	CbGpPWpGaD
Nilutamide—Urinary tract disorder—Methotrexate—bone cancer	0.000113	0.00444	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—RB1—bone cancer	0.000112	0.00486	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000112	0.00483	CbGpPWpGaD
Nilutamide—Urethral disorder—Methotrexate—bone cancer	0.000112	0.0044	CcSEcCtD
Nilutamide—Weight decreased—Doxorubicin—bone cancer	0.000112	0.0044	CcSEcCtD
Nilutamide—Hyperglycaemia—Doxorubicin—bone cancer	0.000111	0.00438	CcSEcCtD
Nilutamide—Pneumonia—Doxorubicin—bone cancer	0.000111	0.00436	CcSEcCtD
Nilutamide—Visual impairment—Methotrexate—bone cancer	0.00011	0.00433	CcSEcCtD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000109	0.00471	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000108	0.00469	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000107	0.00465	CbGpPWpGaD
Nilutamide—Rhinitis—Epirubicin—bone cancer	0.000107	0.00421	CcSEcCtD
Nilutamide—Urinary tract infection—Doxorubicin—bone cancer	0.000107	0.00421	CcSEcCtD
Nilutamide—Hypoaesthesia—Epirubicin—bone cancer	0.000106	0.00418	CcSEcCtD
Nilutamide—Asthenia—Cisplatin—bone cancer	0.000106	0.00417	CcSEcCtD
Nilutamide—Sweating—Doxorubicin—bone cancer	0.000105	0.00415	CcSEcCtD
Nilutamide—Urinary tract disorder—Epirubicin—bone cancer	0.000105	0.00415	CcSEcCtD
Nilutamide—Oedema peripheral—Epirubicin—bone cancer	0.000105	0.00414	CcSEcCtD
Nilutamide—Haematuria—Doxorubicin—bone cancer	0.000105	0.00413	CcSEcCtD
Nilutamide—Urethral disorder—Epirubicin—bone cancer	0.000105	0.00412	CcSEcCtD
Nilutamide—Visual impairment—Epirubicin—bone cancer	0.000103	0.00405	CcSEcCtD
Nilutamide—Diarrhoea—Cisplatin—bone cancer	0.000101	0.00398	CcSEcCtD
Nilutamide—Alopecia—Methotrexate—bone cancer	0.000101	0.00397	CcSEcCtD
Nilutamide—Rhinitis—Doxorubicin—bone cancer	9.89e-05	0.0039	CcSEcCtD
Nilutamide—Hypoaesthesia—Doxorubicin—bone cancer	9.82e-05	0.00387	CcSEcCtD
Nilutamide—Urinary tract disorder—Doxorubicin—bone cancer	9.75e-05	0.00384	CcSEcCtD
Nilutamide—Oedema peripheral—Doxorubicin—bone cancer	9.72e-05	0.00383	CcSEcCtD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.68e-05	0.00419	CbGpPWpGaD
Nilutamide—Urethral disorder—Doxorubicin—bone cancer	9.67e-05	0.00381	CcSEcCtD
Nilutamide—AR—Generic Transcription Pathway—NR1I2—bone cancer	9.63e-05	0.00416	CbGpPWpGaD
Nilutamide—Back pain—Methotrexate—bone cancer	9.6e-05	0.00378	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—MDM2—bone cancer	9.59e-05	0.00415	CbGpPWpGaD
Nilutamide—Visual impairment—Doxorubicin—bone cancer	9.51e-05	0.00375	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	9.47e-05	0.00409	CbGpPWpGaD
Nilutamide—Alopecia—Epirubicin—bone cancer	9.43e-05	0.00371	CcSEcCtD
Nilutamide—Vomiting—Cisplatin—bone cancer	9.38e-05	0.0037	CcSEcCtD
Nilutamide—Rash—Cisplatin—bone cancer	9.3e-05	0.00367	CcSEcCtD
Nilutamide—Dermatitis—Cisplatin—bone cancer	9.3e-05	0.00366	CcSEcCtD
Nilutamide—Ill-defined disorder—Methotrexate—bone cancer	9.21e-05	0.00363	CcSEcCtD
Nilutamide—Anaemia—Methotrexate—bone cancer	9.17e-05	0.00361	CcSEcCtD
Nilutamide—Tension—Epirubicin—bone cancer	9.11e-05	0.00359	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	9.08e-05	0.00392	CbGpPWpGaD
Nilutamide—Nervousness—Epirubicin—bone cancer	9.02e-05	0.00355	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	8.99e-05	0.00389	CbGpPWpGaD
Nilutamide—Back pain—Epirubicin—bone cancer	8.98e-05	0.00354	CcSEcCtD
Nilutamide—Malaise—Methotrexate—bone cancer	8.95e-05	0.00353	CcSEcCtD
Nilutamide—Leukopenia—Methotrexate—bone cancer	8.88e-05	0.0035	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	8.83e-05	0.00382	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.83e-05	0.00382	CbGpPWpGaD
Nilutamide—Nausea—Cisplatin—bone cancer	8.77e-05	0.00345	CcSEcCtD
Nilutamide—Alopecia—Doxorubicin—bone cancer	8.72e-05	0.00344	CcSEcCtD
Nilutamide—Cough—Methotrexate—bone cancer	8.66e-05	0.00341	CcSEcCtD
Nilutamide—Ill-defined disorder—Epirubicin—bone cancer	8.62e-05	0.00339	CcSEcCtD
Nilutamide—Anaemia—Epirubicin—bone cancer	8.58e-05	0.00338	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—CDK4—bone cancer	8.48e-05	0.00366	CbGpPWpGaD
Nilutamide—Chest pain—Methotrexate—bone cancer	8.45e-05	0.00333	CcSEcCtD
Nilutamide—Tension—Doxorubicin—bone cancer	8.43e-05	0.00332	CcSEcCtD
Nilutamide—Malaise—Epirubicin—bone cancer	8.37e-05	0.0033	CcSEcCtD
Nilutamide—Discomfort—Methotrexate—bone cancer	8.35e-05	0.00329	CcSEcCtD
Nilutamide—Nervousness—Doxorubicin—bone cancer	8.34e-05	0.00329	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—JUN—bone cancer	8.34e-05	0.0036	CbGpPWpGaD
Nilutamide—Syncope—Epirubicin—bone cancer	8.33e-05	0.00328	CcSEcCtD
Nilutamide—Leukopenia—Epirubicin—bone cancer	8.31e-05	0.00327	CcSEcCtD
Nilutamide—Back pain—Doxorubicin—bone cancer	8.31e-05	0.00327	CcSEcCtD
Nilutamide—Loss of consciousness—Epirubicin—bone cancer	8.16e-05	0.00322	CcSEcCtD
Nilutamide—Cough—Epirubicin—bone cancer	8.1e-05	0.00319	CcSEcCtD
Nilutamide—Hypertension—Epirubicin—bone cancer	8.02e-05	0.00316	CcSEcCtD
Nilutamide—Ill-defined disorder—Doxorubicin—bone cancer	7.97e-05	0.00314	CcSEcCtD
Nilutamide—Anaemia—Doxorubicin—bone cancer	7.94e-05	0.00313	CcSEcCtD
Nilutamide—Chest pain—Epirubicin—bone cancer	7.91e-05	0.00311	CcSEcCtD
Nilutamide—Hyperhidrosis—Methotrexate—bone cancer	7.83e-05	0.00308	CcSEcCtD
Nilutamide—Discomfort—Epirubicin—bone cancer	7.81e-05	0.00308	CcSEcCtD
Nilutamide—Malaise—Doxorubicin—bone cancer	7.75e-05	0.00305	CcSEcCtD
Nilutamide—Dry mouth—Epirubicin—bone cancer	7.73e-05	0.00305	CcSEcCtD
Nilutamide—Anorexia—Methotrexate—bone cancer	7.72e-05	0.00304	CcSEcCtD
Nilutamide—Syncope—Doxorubicin—bone cancer	7.7e-05	0.00304	CcSEcCtD
Nilutamide—Leukopenia—Doxorubicin—bone cancer	7.69e-05	0.00303	CcSEcCtD
Nilutamide—Oedema—Epirubicin—bone cancer	7.58e-05	0.00299	CcSEcCtD
Nilutamide—Loss of consciousness—Doxorubicin—bone cancer	7.55e-05	0.00298	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—BRAF—bone cancer	7.5e-05	0.00324	CbGpPWpGaD
Nilutamide—Cough—Doxorubicin—bone cancer	7.5e-05	0.00295	CcSEcCtD
Nilutamide—Shock—Epirubicin—bone cancer	7.46e-05	0.00294	CcSEcCtD
Nilutamide—Hypertension—Doxorubicin—bone cancer	7.42e-05	0.00292	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—RB1—bone cancer	7.37e-05	0.00319	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Epirubicin—bone cancer	7.33e-05	0.00289	CcSEcCtD
Nilutamide—Insomnia—Methotrexate—bone cancer	7.32e-05	0.00289	CcSEcCtD
Nilutamide—Chest pain—Doxorubicin—bone cancer	7.31e-05	0.00288	CcSEcCtD
Nilutamide—Paraesthesia—Methotrexate—bone cancer	7.27e-05	0.00287	CcSEcCtD
Nilutamide—Discomfort—Doxorubicin—bone cancer	7.23e-05	0.00285	CcSEcCtD
Nilutamide—Anorexia—Epirubicin—bone cancer	7.22e-05	0.00285	CcSEcCtD
Nilutamide—Dyspnoea—Methotrexate—bone cancer	7.22e-05	0.00284	CcSEcCtD
Nilutamide—Dry mouth—Doxorubicin—bone cancer	7.15e-05	0.00282	CcSEcCtD
Nilutamide—Dyspepsia—Methotrexate—bone cancer	7.13e-05	0.00281	CcSEcCtD
Nilutamide—Decreased appetite—Methotrexate—bone cancer	7.04e-05	0.00277	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	7.02e-05	0.00304	CbGpPWpGaD
Nilutamide—Oedema—Doxorubicin—bone cancer	7.01e-05	0.00276	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Methotrexate—bone cancer	6.99e-05	0.00275	CcSEcCtD
Nilutamide—Pain—Methotrexate—bone cancer	6.92e-05	0.00273	CcSEcCtD
Nilutamide—Shock—Doxorubicin—bone cancer	6.9e-05	0.00272	CcSEcCtD
Nilutamide—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	6.86e-05	0.00297	CbGpPWpGaD
Nilutamide—Insomnia—Epirubicin—bone cancer	6.85e-05	0.0027	CcSEcCtD
Nilutamide—Paraesthesia—Epirubicin—bone cancer	6.8e-05	0.00268	CcSEcCtD
Nilutamide—Hyperhidrosis—Doxorubicin—bone cancer	6.78e-05	0.00267	CcSEcCtD
Nilutamide—Dyspnoea—Epirubicin—bone cancer	6.76e-05	0.00266	CcSEcCtD
Nilutamide—AR—Gene Expression—FUS—bone cancer	6.69e-05	0.00289	CbGpPWpGaD
Nilutamide—Anorexia—Doxorubicin—bone cancer	6.68e-05	0.00263	CcSEcCtD
Nilutamide—Feeling abnormal—Methotrexate—bone cancer	6.67e-05	0.00263	CcSEcCtD
Nilutamide—Dyspepsia—Epirubicin—bone cancer	6.67e-05	0.00263	CcSEcCtD
Nilutamide—Gastrointestinal pain—Methotrexate—bone cancer	6.62e-05	0.00261	CcSEcCtD
Nilutamide—Decreased appetite—Epirubicin—bone cancer	6.59e-05	0.0026	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—EGFR—bone cancer	6.55e-05	0.00283	CbGpPWpGaD
Nilutamide—Gastrointestinal disorder—Epirubicin—bone cancer	6.54e-05	0.00258	CcSEcCtD
Nilutamide—Pain—Epirubicin—bone cancer	6.48e-05	0.00255	CcSEcCtD
Nilutamide—Constipation—Epirubicin—bone cancer	6.48e-05	0.00255	CcSEcCtD
Nilutamide—Body temperature increased—Methotrexate—bone cancer	6.4e-05	0.00252	CcSEcCtD
Nilutamide—Abdominal pain—Methotrexate—bone cancer	6.4e-05	0.00252	CcSEcCtD
Nilutamide—Insomnia—Doxorubicin—bone cancer	6.34e-05	0.0025	CcSEcCtD
Nilutamide—Paraesthesia—Doxorubicin—bone cancer	6.3e-05	0.00248	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—MDM2—bone cancer	6.28e-05	0.00272	CbGpPWpGaD
Nilutamide—Dyspnoea—Doxorubicin—bone cancer	6.25e-05	0.00246	CcSEcCtD
Nilutamide—Feeling abnormal—Epirubicin—bone cancer	6.24e-05	0.00246	CcSEcCtD
Nilutamide—Gastrointestinal pain—Epirubicin—bone cancer	6.2e-05	0.00244	CcSEcCtD
Nilutamide—Dyspepsia—Doxorubicin—bone cancer	6.17e-05	0.00243	CcSEcCtD
Nilutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	6.12e-05	0.00265	CbGpPWpGaD
Nilutamide—Decreased appetite—Doxorubicin—bone cancer	6.1e-05	0.0024	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Doxorubicin—bone cancer	6.05e-05	0.00239	CcSEcCtD
Nilutamide—Pain—Doxorubicin—bone cancer	6e-05	0.00236	CcSEcCtD
Nilutamide—Constipation—Doxorubicin—bone cancer	6e-05	0.00236	CcSEcCtD
Nilutamide—Abdominal pain—Epirubicin—bone cancer	5.99e-05	0.00236	CcSEcCtD
Nilutamide—Body temperature increased—Epirubicin—bone cancer	5.99e-05	0.00236	CcSEcCtD
Nilutamide—Asthenia—Methotrexate—bone cancer	5.81e-05	0.00229	CcSEcCtD
Nilutamide—Feeling abnormal—Doxorubicin—bone cancer	5.78e-05	0.00228	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—CYP3A4—bone cancer	5.76e-05	0.00249	CbGpPWpGaD
Nilutamide—Gastrointestinal pain—Doxorubicin—bone cancer	5.73e-05	0.00226	CcSEcCtD
Nilutamide—Pruritus—Methotrexate—bone cancer	5.73e-05	0.00226	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	5.68e-05	0.00246	CbGpPWpGaD
Nilutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	5.58e-05	0.00241	CbGpPWpGaD
Nilutamide—Abdominal pain—Doxorubicin—bone cancer	5.54e-05	0.00218	CcSEcCtD
Nilutamide—Body temperature increased—Doxorubicin—bone cancer	5.54e-05	0.00218	CcSEcCtD
Nilutamide—Diarrhoea—Methotrexate—bone cancer	5.54e-05	0.00218	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—JUN—bone cancer	5.46e-05	0.00236	CbGpPWpGaD
Nilutamide—Asthenia—Epirubicin—bone cancer	5.44e-05	0.00214	CcSEcCtD
Nilutamide—Pruritus—Epirubicin—bone cancer	5.36e-05	0.00211	CcSEcCtD
Nilutamide—Dizziness—Methotrexate—bone cancer	5.35e-05	0.00211	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—JUN—bone cancer	5.32e-05	0.0023	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.21e-05	0.00225	CbGpPWpGaD
Nilutamide—Diarrhoea—Epirubicin—bone cancer	5.18e-05	0.00204	CcSEcCtD
Nilutamide—Vomiting—Methotrexate—bone cancer	5.15e-05	0.00203	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	5.14e-05	0.00222	CbGpPWpGaD
Nilutamide—Rash—Methotrexate—bone cancer	5.11e-05	0.00201	CcSEcCtD
Nilutamide—Dermatitis—Methotrexate—bone cancer	5.1e-05	0.00201	CcSEcCtD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	5.07e-05	0.00219	CbGpPWpGaD
Nilutamide—Headache—Methotrexate—bone cancer	5.07e-05	0.002	CcSEcCtD
Nilutamide—Asthenia—Doxorubicin—bone cancer	5.03e-05	0.00198	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	5.02e-05	0.00217	CbGpPWpGaD
Nilutamide—Dizziness—Epirubicin—bone cancer	5.01e-05	0.00197	CcSEcCtD
Nilutamide—Pruritus—Doxorubicin—bone cancer	4.96e-05	0.00195	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—GSTP1—bone cancer	4.93e-05	0.00213	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	4.86e-05	0.0021	CbGpPWpGaD
Nilutamide—Vomiting—Epirubicin—bone cancer	4.82e-05	0.0019	CcSEcCtD
Nilutamide—Nausea—Methotrexate—bone cancer	4.81e-05	0.0019	CcSEcCtD
Nilutamide—Diarrhoea—Doxorubicin—bone cancer	4.8e-05	0.00189	CcSEcCtD
Nilutamide—Rash—Epirubicin—bone cancer	4.78e-05	0.00188	CcSEcCtD
Nilutamide—Dermatitis—Epirubicin—bone cancer	4.77e-05	0.00188	CcSEcCtD
Nilutamide—Headache—Epirubicin—bone cancer	4.75e-05	0.00187	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	4.69e-05	0.00203	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NR1I2—bone cancer	4.64e-05	0.002	CbGpPWpGaD
Nilutamide—Dizziness—Doxorubicin—bone cancer	4.64e-05	0.00183	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	4.63e-05	0.002	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.53e-05	0.00196	CbGpPWpGaD
Nilutamide—Nausea—Epirubicin—bone cancer	4.5e-05	0.00177	CcSEcCtD
Nilutamide—Vomiting—Doxorubicin—bone cancer	4.46e-05	0.00176	CcSEcCtD
Nilutamide—Rash—Doxorubicin—bone cancer	4.42e-05	0.00174	CcSEcCtD
Nilutamide—Dermatitis—Doxorubicin—bone cancer	4.42e-05	0.00174	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—GSTP1—bone cancer	4.4e-05	0.0019	CbGpPWpGaD
Nilutamide—Headache—Doxorubicin—bone cancer	4.39e-05	0.00173	CcSEcCtD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	4.34e-05	0.00188	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EGFR—bone cancer	4.29e-05	0.00186	CbGpPWpGaD
Nilutamide—Nausea—Doxorubicin—bone cancer	4.16e-05	0.00164	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—GSTP1—bone cancer	4.01e-05	0.00173	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	3.96e-05	0.00171	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TP53—bone cancer	3.61e-05	0.00156	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.56e-05	0.00154	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NDUFA12—bone cancer	3.45e-05	0.00149	CbGpPWpGaD
Nilutamide—AR—Gene Expression—EIF2S1—bone cancer	3.42e-05	0.00148	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NDUFA12—bone cancer	3.08e-05	0.00133	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.99e-05	0.00129	CbGpPWpGaD
Nilutamide—AR—Gene Expression—EZH2—bone cancer	2.98e-05	0.00129	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NT5C3A—bone cancer	2.86e-05	0.00124	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NDUFA12—bone cancer	2.81e-05	0.00122	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NT5C3A—bone cancer	2.55e-05	0.0011	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NT5C3A—bone cancer	2.33e-05	0.00101	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ENO2—bone cancer	1.25e-05	0.000542	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—DHFR—bone cancer	1.16e-05	0.000503	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ENO2—bone cancer	1.12e-05	0.000484	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GNA11—bone cancer	1.09e-05	0.00047	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—DHFR—bone cancer	1.04e-05	0.000449	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ENO2—bone cancer	1.02e-05	0.000441	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP3A4—bone cancer	9.86e-06	0.000426	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.81e-06	0.000424	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GNA11—bone cancer	9.7e-06	0.000419	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—DHFR—bone cancer	9.47e-06	0.000409	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GNA11—bone cancer	8.85e-06	0.000382	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP3A4—bone cancer	8.8e-06	0.00038	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.75e-06	0.000378	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTP1—bone cancer	8.43e-06	0.000364	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP3A4—bone cancer	8.02e-06	0.000347	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.98e-06	0.000345	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTP1—bone cancer	7.52e-06	0.000325	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTP1—bone cancer	6.86e-06	0.000297	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTGS2—bone cancer	4.37e-06	0.000189	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTGS2—bone cancer	3.9e-06	0.000168	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTGS2—bone cancer	3.55e-06	0.000154	CbGpPWpGaD
